Key result
Short-duration initial intensive rivaroxaban shows no significant difference in VTE recurrence vs standard duration.
Why the study?
Does a short (1-8 days) or intermediate (9-16 days) duration of initial intensive rivaroxaban therapy (15 mg twice daily) affect VTE recurrence and major bleeding compared with the standard duration (17-24 days) in Japanese patients with acute VTE?
Cohort (n=667)
Independent, blinded clinical events committee adjudicated the outcomes
Yes
Does a short (1-8 days) or intermediate (9-16 days) duration of initial intensive rivaroxaban therapy (15 mg twice daily) affect VTE recurrence and major bleeding compared with the standard duration (17-24 days) in Japanese patients with acute VTE?
Supports the standard 21-day (17-24 days) initial intensive rivaroxaban regimen (15 mg twice daily) in Japanese patients with acute VTE, as shortening the intensive phase to 1-8 days tended to increase VTE recurrence and 9-16 days was associated with higher bleeding rates.
Answers are grounded in this paper and cite their sources.
Short initial rivaroxaban was associated with higher VTE recurrence; leaves open optimal duration in observational cohorts pending randomized trials.
Background Rivaroxaban, a direct oral anticoagulant, is used as a first-line treatment to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, whether 21 days is optimal for the initial treatment duration has not been investigated. Methods and Results In this subanalysis of the prospective multicenter observational J’xactly study, which included 1,039 Japanese patients with acute symptomatic/asymptomatic DVT/PE who were prescribed rivaroxaban, the VTE recurrence rate and incidence of bleeding complications were assessed in 667 patients who underwent intensive rivaroxaban treatment (15 mg, twice daily) for a short (1–8 days), intermediate (9–16), or standard (17–24) duration. The short treatment duration group showed a tendency for increased VTE recurrence/aggravation compared with the standard treatment duration group (6.10% vs. 2.60% per patient-year). The intermediate treatment duration group showed a higher incidence of bleeding events than the standard treatment duration group (9.34% vs. 2.16% per patient-year), without major differences in patient characteristics between the groups. Conclusions In this subanalysis of the real-world observational J’xactly study of VTE treatment and prevention in Japanese patients with acute symptomatic/asymptomatic DVT/PE, the standard initial intensive rivaroxaban treatment duration (17–24 days) appeared to be safe and effective, providing important insights into the clinical outcomes of the initial rivaroxaban treatment duration in this population.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2023) conducted a cohort in Acute symptomatic or asymptomatic venous thromboembolism (deep vein thrombosis, pulmonary embolism, or both) (n=667). Short (1-8 days) or intermediate (9-16 days) duration of initial intensive rivaroxaban therapy (15 mg twice daily) vs. Standard duration (17-24 days) of initial intensive rivaroxaban therapy (15 mg twice daily) was evaluated on Recurrence or aggravation of symptomatic venous thromboembolism (short vs. standard duration) (HR 2.35, 95% CI 0.89-6.23). Short-duration (1-8 days) initial intensive rivaroxaban showed a trend toward higher VTE recurrence vs standard duration (17-24 days).
Synapse has enriched 10 related papers. Consider them for comparative context: